Switching IBD med from IV to a shot: does it work?
NCT ID NCT07123350
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study reviews medical records of 120 adults with inflammatory bowel disease (Crohn's or ulcerative colitis) who switched from intravenous to subcutaneous (under-the-skin) vedolizumab. Researchers want to see if patients stay in remission and what dosing patterns doctors use in real-world practice. No new treatments are given—it's an observational look at standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37211, United States
Conditions
Explore the condition pages connected to this study.